Can-Fite BioPharma (NYSE:CANF) Trading Up 3% – Should You Buy?

Can-Fite BioPharma Ltd. (NYSE:CANF) shares were up 3% during mid-day trading on Monday . The stock traded as high as $4.32 and last traded at $4.13. Approximately 23,573 shares traded hands during mid-day trading, a decline of 73% from the average daily volume of 86,648 shares. The stock had previously closed at $4.01.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on CANF shares. D. Boral Capital decreased their price objective on shares of Can-Fite BioPharma from $220.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, December 17th. Zacks Research upgraded Can-Fite BioPharma to a “hold” rating in a research note on Thursday, November 6th. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, November 4th. Finally, D Boral Capital downgraded Can-Fite BioPharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 24th. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Can-Fite BioPharma has a consensus rating of “Moderate Buy” and an average target price of $65.00.

Can-Fite BioPharma Stock Up 3.0%

The company has a market capitalization of $5.41 million, a price-to-earnings ratio of -2.31 and a beta of 1.03. The stock has a 50 day simple moving average of $4.97 and a 200 day simple moving average of $9.50.

Institutional Investors Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Rhumbline Advisers increased its stake in Can-Fite BioPharma Ltd. (NYSE:CANF) by 42.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,268 shares of the company’s stock after purchasing an additional 11,388 shares during the quarter. Rhumbline Advisers owned about 1.08% of Can-Fite BioPharma worth $57,000 at the end of the most recent quarter. 21.00% of the stock is currently owned by institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).